Michael Ament
Neurology · Denver, CONPI 1437111010
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $381,130 of the $457,389 with a category attached, or 83.3%. 21 manufacturers reported payments, led by Lilly USA, LLC at 41.7% of the total. Reporting peaked in 2021 at $146,651 and has fallen 99.4% since, to $823 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 805 payments — averaging $568.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$191K
- AbbVie$126K
- Biohaven Pharmaceutical Holding Company Ltd.$42K
- Teva Pharmaceuticals USA, Inc.$38K
- Biohaven Pharmaceuticals, Inc.$27K
- Amgen$16K
- plus $17K from 15 others
What the payments were for
- Consulting fees$43,0719%
- Speaking & faculty fees$381,13083%
- Grants$440%
- Travel & lodging$18,1904%
- Food & beverage$13,7403%
- Education$1,2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 345 | $190,785 |
| AbbVie(2 entities) | 182 | $125,560 |
| Biohaven Pharmaceutical Holding Company Ltd. | 56 | $42,368 |
| Teva Pharmaceuticals USA, Inc. | 62 | $37,514 |
| Biohaven Pharmaceuticals, Inc. | 56 | $27,378 |
| Amgen | 33 | $16,366 |
| Biodelivery Sciences International, Inc. | 11 | $8,619 |
| Lundbeck LLC | 22 | $5,785 |
| Eli Lilly | 4 | $2,206 |
| Axsome Therapeutics, Inc. | 5 | $290 |
| Pfizer | 9 | $166 |
| Impel Pharmaceuticals Inc. | 1 | $81 |
| Bristol Myers Squibb | 5 | $81 |
| Upsher-smith Laboratories LLC | 4 | $54 |
| Assertio Therapeutics, Inc. | 3 | $44 |
| Promius Pharma LLC | 2 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$457,389 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 89 | $73,304 |
| Nurtec OdtRimegepant Sulfate | 42 | $51,469 |
| QuliptaAtogepant | 17 | $26,017 |
| Diclofenac Sodium | 25 | $323 |
| Phenytoin Sodium Extended | 12 | $132 |
| Duloxetine Hcl | 20 | $124 |
| Estradiol | 11 | $97 |
| Gabapentin | 15 | $47 |
| Meloxicam | 13 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $166 | $51,46942 claims |
| AbbVieQulipta | $125,560 | $26,01717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Adam WolffDenver$364K
- Shankar PerumalDenver$61K
- Jinny TaveeDenver$58K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
- Tamara MillerFort Collins$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.